David Chu

发表

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer

Doron Lipson, Gary L Rosner, Christopher D Gocke, 2016, Clinical Cancer Research.

Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component

A. Cimino-Mathews, B. Park, S. Wheelan, 2017, Clinical Cancer Research.

Detection fidelity of AR mutations in plasma derived cell-free DNA

B. Trock, E. Antonarakis, B. Park, 2017, Oncotarget.

NOTCH1 PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model

B. Park, D. Rosen, P. Hurley, 2022, Oncotarget.

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.

A. Chinnaiyan, Dafydd G. Thomas, S. Tomlins, 2018, Cancer research.

A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.

B. Park, D. Laheru, J. Axilbund, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.

B. Katzenellenbogen, J. Katzenellenbogen, K. Nettles, 2017, Cancer research.

Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA.

B. Park, P. Hurley, J. Beaver, 2015, Clinical biochemistry.

Single-Nucleotide Polymorphism Leading to False Allelic Fraction by Droplet Digital PCR.

B. Park, David Chu, Daniel J. Zabransky, 2017, Clinical chemistry.

The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies

B. Park, R. Roden, D. Rosen, 2019, Breast Cancer Research and Treatment.

ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition.

C. Benz, B. Hann, G. Scott, 2017, Oncotarget.

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation

P. Argani, J. Hicks, A. D. De Marzo, 2016, Oncotarget.

HER2 missense mutations have distinct effects on oncogenic signaling and migration

R. Bose, A. Cimino-Mathews, K. Konstantopoulos, 2015, Proceedings of the National Academy of Sciences.

Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes

B. Park, A. Meeker, C. Heaphy, 2015, Oncotarget.

TMSB 4 Y is a Candidate Tumor Suppressor on the Y Chromosome and is Deleted in Male Breast Cancer

P. Argani, B. Park, A. Meeker, 2016 .

TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer

P. Argani, B. Park, A. Meeker, 2015, Oncotarget.

Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones.

M. Sanders, B. Park, D. Rosen, 2021, The Journal of clinical investigation.

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer

B. Trock, E. Antonarakis, B. Park, 2019, JCO precision oncology.

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models

Adrian V. Lee, B. Park, S. Oesterreich, 2017, Breast Cancer Research.

Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.

Dhanashree S. Kelkar, A. Pandey, A. Madugundu, 2019, The Journal of clinical investigation.

Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer

Antonio C. Wolff, Leslie Cope, Vered Stearns, 2014, Clinical Cancer Research.

Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction.

P. Argani, S. Wheelan, J. Beaver, 2014, Human pathology.

Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells

Adrian V. Lee, B. Park, S. Oesterreich, 2018, Endocrinology.

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models

Adrian V. Lee, B. Park, S. Oesterreich, 2017, Breast Cancer Research.

Liquid biopsy: unlocking the potentials of cell-free DNA

B. Park, David Chu, David Chu, 2017, Virchows Archiv.

NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability

R. Scharpf, B. Park, M. Mohseni, 2015, Proceedings of the National Academy of Sciences.

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Daniel F. Hayes, Arul M. Chinnaiyan, Heather A. Parsons, 2015, Clinical Cancer Research.

Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA

J. Wolinsky, B. Park, C. Meyer, 2016, Cancer.

A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations

A. Pandey, Xinyan Wu, M. S. Zahari, 2015, Proteomics.

Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity

B. Park, Aparna Pallavajjala, David Chu, 2018, Practical laboratory medicine.

ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition

C. Benz, B. Hann, G. Scott, 2016, Oncotarget.

ESR 1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Daniel F. Hayes, Arul M. Chinnaiyan, Heather Parsons, 2015 .

PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity

B. Park, D. Rosen, P. Hurley, 2017, Breast Cancer Research and Treatment.

TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer

P. Argani, B. Park, A. Meeker, 2015, Oncotarget.